Reuters logo
Gilead sciences to pay Merck $2.54 bln in hepatitis c royalties -court verdict
December 15, 2016 / 9:56 PM / a year ago

Gilead sciences to pay Merck $2.54 bln in hepatitis c royalties -court verdict

Dec 15 (Reuters) - A federal jury in Delaware on Thursday awarded Merck & Co $2.54 billion in royalties in a patent lawsuit against Gilead Sciences Inc over Gilead’s blockbuster hepatitis C drugs Sovaldi and Harvoni.

The jury reached the verdict following a nearly two-week trial, finding that a Merck patent on hepatitis C drugs was valid. (Reporting by Brendan Pierson in New York; Editing by Dan Grebler)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below